丙型肝炎微消除研究进展*

doi:10.3969/j.issn.1672-5069.2026.01.003

摘要/Abstract

Key words: Hepatitis C, Hepatitis C virus, Micro-elimination, Direct acting antivirals

黎健, 罗磊, 杨文龙. 丙型肝炎微消除研究进展^*[J]. 实用肝脏病杂志, 2026, 29(1): 9-12.

Li Jian, Luo Lei, Yang Wenlong. Micro-elimination of hepatitis C viral infection[J]. Journal of Practical Hepatology, 2026, 29(1): 9-12.

[1] 王焱,韩军,杨美蓉.三种DAAs方案治疗慢性丙型肝炎患者两年随访研究.实用肝脏病杂志,2024,27(1):32-35.
[2] World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016-2021: actions for impact. Geneva:World Health Organization, 2021.
[3] World Health Organization. Global health sector strategy on viral hepatitis 2016-2021.Geneva:World Health Organization, 2016.
[4] Collaborators P O H. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol, 2022, 7(5): 396-415.
[5] Lazarus J V, Wiktor S, Colombo M, et al. Micro-elimination - A path to global elimination of hepatitis C. J Hepatol, 2017, 67(4): 665-666.
[6] 蒋荣猛,罗新华,窦晓光,等.丙型病毒性肝炎诊治质量改进专家共识.中华实验和临床感染病杂志(电子版), 2023, 17(6): 385-389.
[7] 彭小波, 李强, 王福超. 农村地区丙型病毒性肝炎知识知晓情况调查.中国艾滋病性病, 2021, 27(7): 770-771.
[8] 王怀, 邱倩, 袁千里, 等. 2021年北京市社区居民和医务人员丙型肝炎防治知识知晓情况调查. 疾病监测, 2023, 38(7): 854-858.
[9] 中华人民共和国国家卫生和计划生育委员会. WS 213—2018 丙型肝炎诊断.临床肝胆病杂志, 2018, 34(8): 1619-1621.
[10] 王百锁, 尤海菲, 胡婷, 等. 陕西省医务人员丙型肝炎相关知识认知情况调查.中国艾滋病性病, 2018, 24(10): 1054-1055.
[11] Health N, Commission F P, Development N, 等. 中国病毒性肝炎防治规划(2017-2020年). 中国病毒病杂志, 2018, 8(1): 1-5.
[12] 冯小飞, 丁国伟, 俞海亮, 等. 医疗机构丙型肝炎诊断治疗现况研究.中国艾滋病性病, 2020, 26(3): 247-249.
[13] 中联肝健康促进中心, 中华医学会肝病学分会, 中华医学会检验医学分会, 等. 中国丙型病毒性肝炎院内筛查管理流程(试行).临床肝胆病杂志, 2021, 37(7): 1534-1539.
[14] 国家卫生健康委办公厅, 科技部办公厅, 工业和信息化部办公厅, 等. 消除丙型肝炎公共卫生危害行动工作方案(2021-2030年). 2021-08-31.
[15] Chunmei Li, Jia Wei, Li. H. Supporting HCV elimination through medical education tours project in southwest China: AASLD, 2023.
[16] Chunfang You, Yangyang Pu, Wei Dong, et al. Collaborative in-hospital HCV micro-elimination model and call back strategy for diagnosed but untreated patients in China: AASLD, 2023.
[17] Liu L, Xu H, Hu Y, et al. Hepatitis C screening in hospitals: find the missing patients. Virol J, 2019, 16(1): 47.
[18] Huang C F, Wu P F, Yeh M L, et al. Scaling up the in-hospital hepatitis C virus care cascade in Taiwan. Clin Mol Hepatol, 2021, 27(1): 136-143.
[19] Shifu Li, Wengbing Dong, Yang Luo, et al. A government-leading multi-organization collaborative model for HCV elimination in Yuxi, Yunnan: APASL 2023.
[20] Isfordink C J, van Dijk M, Brakenhoff S M, et al. Hepatitis C elimination in the netherlands (CELINE): how nationwide retrieval of lost to follow-up hepatitis C patients contributes to micro-elimination. Eur J Intern Med, 2022, 101: 93-97.
[21] Huang JF, Hsieh MY, Wei YJ, et al. Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study).Hepatol Int, 2021, 16(1): 59-67.
[22] Mitruka K, Tsertsvadze T, Butsashvili M, et al. Launch of a nationwide eepatitis C elimination program--Georgia, April 2015. MMWR Morb Mortal Wkly Rep, 2015, 64(28): 753-757.
[23] Tsertsvadze T, Gamkrelidze A, Chkhartishvili N, et al. Three years ofprogress toward achieving hepatitis C elimination in the country of Georgia, April 2015-March 2018. Clin Infect Dis, 2020, 71(5): 1263-1268.
[24] Averhoff F, Lazarus J V, Sergeenko D, et al. Excellence in viral hepatitis elimination - Lessons from Georgia. J Hepatol, 2019, 71(4): 645-647.
[25] Dolmazashvili E, Sharvadze L, Abutidze A, et al. Treatment of hepatitis C in primary health care in the country of Georgia. Clin Liver Dis (Hoboken), 2022, 20(5): 175-178.
[26] Olafsson S, Fridriksdottir R H, Love T J, et al. Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study. Lancet Gastroenterol Hepatol, 2021, 6(8): 628-637.
[27] 罗新华, 梁跃东, 彭虹, 等. 从全球丙型肝炎微消除模式到贵州省慢性丙型肝炎健康教育模式的探索. 中华肝脏病杂志, 2020, 28(10): 816-819.
[28] Shiha G, Soliman R, Mikhail N N H, et al. Reduced incidence of hepatitis C in 9 villages in rural Egypt: Progress towards national elimination goals. J Hepatol, 2021, 74(2): 303-311.
[29] 饶慧瑛, 李明阳, 魏来. 消除丙型肝炎, 我们的进展、挑战和希望. 中华肝脏病杂志, 2020, 28(10): 809-811.
[30] Bao Y, Larney S, Peacock A, et al. Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis. Int J Drug Policy, 2019, 70: 87-93.
[31] Martin N K, Vickerman P, Foster G R, et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol, 2011, 54(6): 1137-1144.
[32] 吴涛, 林锋, 王姣, 等. 中国吸毒人群中的丙型肝炎消除:挑战、策略和经验.中华肝脏病杂志, 2022, 30(9): 1002-1006.
[33] Bartlett S R, Fox P, Cabatingan H, et al. Demonstration of near-elimination of hepatitis C virus among a prison population: the lotus glen correctional centre hepatitis C treatment project. Clin Infect Dis, 2018, 67(3): 460-463.
[34] Tejera-Pérez R J, Iglesias-Gómez A, Oliva-Oliva A, et al. Real-life experience of hepatitis C treatment in a Spanish prison. Rev Esp Quimioter, 2022, 35(3): 273-278.
[35] Marc L, Mihaescu A, Lupusoru R, et al. Hepatitis C and hepatitis B virus infection in hemodialysis patients after nationwide direct antiviral agents therapy-experience of 10 Romanian HD centers. Int Urol Nephrol, 2023, 55(11): 2951-2958.
[36] Gan L, Wang D, Bieber B, et al. Hepatitis C prevalence, incidence, and treatment in Chinese hemodialysis patients: results from the dialysis outcomes and practice patterns study-China (2019-21). Front Med (Lausanne), 2022, 9: 910840.
[37] Huang C F, Dai C Y, Wang C W, et al. Therapy as prevention toward HCV elimination in maintenance hemodialysis: a multi-center, prospective cohort study. Clin Kidney J, 2023, 16(12): 2429-2436.
[38] Chaillon A, Rand E B, Reau N, et al. Cost-effectiveness of universal hepatitis C virus screening of pregnant women in the United States. Clin Infect Dis, 2019, 69(11): 1888-1895.
[39] Thompson L A, Plitt S S, Doucette K, et al. Evaluation and comparison of risk-based and universal prenatal HCV screening programs in Alberta, Canada. J Hepatol, 2023, 79(5): 1121-1128.
[40] 刘奕杉, 张兰婷, 赵蕴玉, 等. 妊娠期妇女和儿童丙型肝炎的管理.临床肝胆病杂志, 2024, 40(4): 654-658.
[41] Torres H A, Mustafayev K, Juneau R P, et al. Implementation of universal hepatitis C virus screening in a tertiary cancer center. J Natl Compr Canc Netw, 2024, 22(2d): 1-5.
[42] American Association for the Study of Liver Diseases. The national hepatitis C elimination program-AASLD's coalition and call to action.Hepatology (Baltimore, Md.), 2023, 78(2): 371-374.
[43] 罗碧芬, 金晶兰, 饶慧瑛, 等. 磷酸依米他韦联合索磷布韦治疗慢性丙型肝炎病毒感染的有效性和安全性. 中华传染病杂志, 2019, 37(7): 420-429.
[44] Hollande C, Parlati L, Pol S. Micro-elimination of hepatitis C virus. Liver Int, 2020, 40 (Suppl 1): 67-71.

丙型肝炎微消除研究进展^*

Micro-elimination of hepatitis C viral infection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	蒋婵娟, 邵靖渊, 徐林. 艾尔巴韦/格拉瑞韦治疗慢性肾病合并慢性丙型肝炎患者疗效和安全性研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 822-825.
[2]	王超杰, 谢群, 姜海, 周宝勤, 杨亮. 3D方案治疗初始治疗的基因1b型慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 826-829.
[3]	郝帅, 王梓依, 张心怡, 张粉娜, 苏娜, 贺娜. 常态化随访实施院内丙型肝炎微消除策略效果评价^*[J]. 实用肝脏病杂志, 2025, 28(5): 675-678.
[4]	刘志东, 李文松, 高震, 孙李妍, 丁琪. 达拉他韦和阿舒瑞韦治疗初治的基因1b型慢性丙型肝炎患者疗效及其外周血淋巴细胞亚群的变化^*[J]. 实用肝脏病杂志, 2025, 28(5): 679-682.
[5]	辛文渊, 李玉薇, 吴君. 达卡他韦联合阿舒瑞韦治疗基因1b型慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 683-686.
[6]	樊予惠, 黄素培, 侯爱敏, 王世英. 索磷布韦联合达诺瑞韦治疗基因3型初治的慢性丙型肝炎患者疗效和安全性分析^*[J]. 实用肝脏病杂志, 2025, 28(4): 517-520.
[7]	林丽泉, 白晓苏, 张爱兰, 程小桂. 利托那韦增强的达诺瑞韦联合索磷布韦和利巴韦林方案治疗基因3型慢性丙型肝炎患者疗效和安全性研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 521-524.
[8]	施海群, 钱杰, 沈国倩, 赵萌. 索磷布韦联合维帕他韦治疗丙型肝炎肝硬化患者临床疗效和门脉超声检查指标变化研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 585-588.
[9]	王浩, 王清园, 沈琼, 许宇文. 聚乙二醇化干扰素α-2a联合艾尔巴韦/格拉瑞韦治疗慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 346-349.
[10]	祁婧, 赵小婷, 王婷婷, 高瑞. 接受索磷布韦/达拉他韦治疗的慢性丙型肝炎患者血清NOD样受体热蛋白结构域相关蛋白3水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(2): 194-197.
[11]	王菲, 刘迎宾, 赵媛媛. 聚乙二醇干扰素α-2a联合艾尔巴韦/格拉瑞韦治疗慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 40-43.
[12]	朱中华, 胡均贤, 李炎. 索非布韦/达克拉韦治疗CHC患者血清血管性血友病因子和可溶性血管黏附因子1水平变化^*[J]. 实用肝脏病杂志, 2024, 27(6): 836-839.
[13]	张珂瓈, 童静, 李昌平. 接受达拉他韦和阿舒瑞韦治疗的初治基因1b型慢性丙型肝炎患者疗效评价^*[J]. 实用肝脏病杂志, 2024, 27(6): 840-843.
[14]	乔进, 赵彦, 窦志华. 半量索磷布韦联合全量达卡他韦治疗终末期肾病合并慢性丙型肝炎患者疗效和耐受性评价^*[J]. 实用肝脏病杂志, 2024, 27(6): 844-847.
[15]	李靓, 段丽祥, 孙晓红. NucliSens miniMag与QIAamp系统检测血清丙型肝炎病毒RNA效能比较^*[J]. 实用肝脏病杂志, 2024, 27(6): 848-851.